

Figure S1. A, B. The UCA1 mRNA levels were reduced in Mpanc96 and HPAF-II cells transfected with sh-UCA1, whereas the UCA1 mRNA levels were increased after UCA1 overexpression in PaTu8988 and PANC-1 cells. C. Prediction of the RNA-protein interaction of UCA1 with hnRNPA2B1 using the catRAPID algorithm. D, E. The mRNA levels of UCA1 and KRAS were detected by qRT-PCR in Mpanc96 and HPAF-II cells after transfection with pSL-MS2-12X, UCA1-wt or UCA1-mut3 (Δ 271-282, mutated hnRNPA2B1 binding site in UCA1), respectively. (*P<0.05, **P<0.01, ***P<0.001).



Figure S2. A. A schematic diagram of RNA immunoprecipitation (RIP) using MS2. B. Candidate miRNAs interacting with UCA1 were identified by the RIP assay. C. The expression of miR-590-3p in miR-590-3p-overexpressing cells was assessed by qRT-PCR. D, E. KRAS protein and mRNA expression levels were assessed in 4 PDAC cell lines by western blotting and qRT-PCR, respectively. F, G. The effect of KRAS on UCA1 expression was explored by qRT-PCR in Mpanc96/HPAF-II cells with KRAS knockdown and PaTu8988/Panc-1 cells overexpressing KRAS.



Figure S3. A schematic showing the results of this study. UCA1 is upregulated in PDAC. Moreover, UCA1 promotes the activity and expression of oncogenic KRAS, which, through interacting with hnRNPA2B1 and sponging miR-590-3p, is involved in the growth and progression of PDAC.